Sanofi to pay up to $315M for Kyowa MAb
French drug major Sanofi-Aventis has signed a collaboration agreement with Japan's Kyowa Hakko Kirin for rights to develop the latter's anti-LIGHT fully-human monoclonal antibody, which will strengthen the Paris-based firm's pipeline in the field of inflammation.
The total global antibody therapeutics market has been forecast to reach a value of $26.0 billion by 2010, compared with around $20.0 billion in 2007.
Under the terms of the deal, Kyowa Hakko will receive an upfront payment as well as milestones depending on the successful achievement of certain development steps. The total value of these payments could reach $315.0 million. The Japanese firm will also be entitled to royalties on sales when the product is commercialized.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze